PATENT CLAIM ANALYSIS

Application Number: 15967442
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "001850"]

Abstract:
Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Claim (Index 20):
The method of  claim 11 , wherein the radionuclide is bismuth -213 , caesium -131 , caesium -137 , chromium -51 , cobalt -57 , cobalt -60 , copper -64 , copper -67 , dysprosium -165 , erbium -169 , fluorine -18 , gallium -68 , gallium -68 , germanium -68 , holmium -166 , indium -111 , iodine -123 , iodine -124 , iodine -125 , iodine -131 , iridium -192 , iron -59 , krypton -81m , lead -212 , lutetium -177 , molybdenum -99 , palladium -103 , phosphorus -32 , potassium -42 , radium -223 , rhenium -186 , rhenium -188 , rubidium -81 , rubidium -82 , samarium -153 , selenium -75 , sodium -24 , strontium -89 , strontium -89 , technetium -99m , thallium -201 , xenon -133 , ytterbium -169 , ytterbium -177 , or yttrium -90 .

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15508391', '15062740', '15346743', '15135151', '15222734']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7702930119133419
- 35 USC 102 Novelty (BERT): 0.5297272521455292
- Combined Prediction Score: 0.7462364359365605
- Mean Citation Score: 314.46507800000006
- Max Citation Score: 329.28775
- Similarity Product: 171.4012232742459

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test